Shopping Cart
Remove All
Your shopping cart is currently empty
Anticancer agent 306
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T218232 Copy Product Info
🥰Excellent
Anticanceragent 306, a spirotetraacid derivative, serves as an inhibitor of MMP1, MMP7, and PLK1. It exhibits antiproliferative effects on H1299, RKO, and MCF-7 cells, with IC50 values of 19.25 μM, 3.29 μM, and 102.36 μM, respectively. The compound induces cell cycle arrest by upregulating p21 protein and downregulating CCND1 and CCNB1 proteins, and it modulates Bcl-2 and Bax expression to trigger apoptosis (apoptosis). Furthermore, by downregulating MMP1 and MMP7 proteins, it inhibits tumor invasion and metastasis. Anticanceragent 306 is applicable in studies related to lung cancer, colorectal cancer, and breast cancer.
Anticancer agent 306
Cas No. 3043892-01-6
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Anticanceragent 306, a spirotetraacid derivative, serves as an inhibitor of MMP1, MMP7, and PLK1. It exhibits antiproliferative effects on H1299, RKO, and MCF-7 cells, with IC50 values of 19.25 μM, 3.29 μM, and 102.36 μM, respectively. The compound induces cell cycle arrest by upregulating p21 protein and downregulating CCND1 and CCNB1 proteins, and it modulates Bcl-2 and Bax expression to trigger apoptosis (apoptosis). Furthermore, by downregulating MMP1 and MMP7 proteins, it inhibits tumor invasion and metastasis. Anticanceragent 306 is applicable in studies related to lung cancer, colorectal cancer, and breast cancer. |
| In vitro | Anticancer agent 306 (8D) effectively inhibits the proliferation of H1299, RKO, and MCF-7 cells, with IC50 values of 19.25 μM, 3.29 μM, and 102.36 μM, respectively. At concentrations of 10-40 μg/mL, it exhibits dose-dependent downregulation of MMP1, MMP7, PLK1, CCND1, and Bcl-2, while upregulating p21, Bax, caspase-3, and caspase-8 in H1299 and RKO cells. Furthermore, it induces G1 phase cell cycle arrest in these cells, decreasing the proportion of cells in the S and G2 phases. Additionally, anticancer agent 306 promotes both early and late apoptosis in H1299 and RKO cells through a mitochondrial pathway in a dose-dependent manner. |
| Molecular Weight | 382.28 |
| Formula | C19H21Cl2NO3 |
| Cas No. | 3043892-01-6 |
| Smiles | O=C1NC2(C(OC(=O)CC(C)C)=C1C=3C=CC(Cl)=CC3Cl)CCCC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Anticancer agent 306 in vitro | Anticancer agent 306 formula | Anticancer agent 306 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.